Intranasal drug developer Optinose has announced the appointment of Ramy Mahmoud as CEO, succeeding Peter Miller. Mahmoud has served as Optinose’s President and Chief Operating Officer since 2010; before joining the company, he served in a number of roles at Johnson & Johnson, including Chief Medical Officer.
The company also announced that it expects to submit an sNDA for Xhance fluticasone propionate nasal spray for the treatment of chronic sinusitis within the next month. Xhance was approved by the FDA in 2017 for the treatment of nasal polyps. In June 2022, Optinose announced that the Phase 3 ReOpen2 trial of Xhance for chronic sinusitis met its primary endpoints.
Miller commented, “It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients’ lives. . . . Ramy is a great friend and an exceptional leader. We have done things side by side since partnering in 2010 to start Optinose, Inc. and I am very confident that he will lead the company to new heights.”
Mahmoud said, “It has been a privilege to have the opportunity to partner with Peter; he has led the company with vision, energy, and passion through many important milestones. I am personally grateful for the time we have spent working together, and I know I speak on behalf of all my colleagues at Optinose when I say we deeply appreciate his many important contributions to the organization.”
Read the Optinose press release.
